Copyright
©The Author(s) 2024.
World J Exp Med. Jun 20, 2024; 14(2): 93689
Published online Jun 20, 2024. doi: 10.5493/wjem.v14.i2.93689
Published online Jun 20, 2024. doi: 10.5493/wjem.v14.i2.93689
Figure 1 The pathobiology of male obesity-related secondary hypogonadism.
E: Estradiol; GnRH: Gonadotropin-releasing hormone; LH: Luteinizing hormone; T: Testosterone.
Figure 2 Therapeutic benefits of androgen replacement therapy in male obesity-related secondary hypogonadism.
CV: Cardiovascular; SBP: Systolic blood pressure.
- Citation: Shenoy MT, Mondal S, Fernandez CJ, Pappachan JM. Management of male obesity-related secondary hypogonadism: A clinical update. World J Exp Med 2024; 14(2): 93689
- URL: https://www.wjgnet.com/2220-315x/full/v14/i2/93689.htm
- DOI: https://dx.doi.org/10.5493/wjem.v14.i2.93689